Award Number: W81XWH-11-1-0585 TITLE: ROLE OF NATURAL KILLER T CELLS IN IMMUNOGENIC CHEMOTHERAPY FOR BREAST CANCER

[1]  R. Flavell,et al.  Vγ4 γδ T Cell-Derived IL-17A Negatively Regulates NKT Cell Function in Con A-Induced Fulminant Hepatitis , 2011, The Journal of Immunology.

[2]  K. Mills,et al.  Caspase-1–Processed Cytokines IL-1β and IL-18 Promote IL-17 Production by γδ and CD4 T Cells That Mediate Autoimmunity , 2011, The Journal of Immunology.

[3]  H. Oberg,et al.  Modulation of γδ T cell responses by TLR ligands , 2011, Cellular and Molecular Life Sciences.

[4]  B. Silva-Santos,et al.  Searching for “signal 2”: costimulation requirements of γδ T cells , 2011, Cellular and Molecular Life Sciences.

[5]  M. Swain,et al.  Protective role of interleukin-17 in murine NKT cell-driven acute experimental hepatitis. , 2010, The American journal of pathology.

[6]  W. Born,et al.  gammadelta T cell subsets: a link between TCR and function? , 2010, Seminars in immunology.

[7]  M. Bonneville,et al.  γδ T cell effector functions: a blend of innate programming and acquired plasticity , 2010, Nature Reviews Immunology.

[8]  S. Kaufmann,et al.  Retracted: α‐GalCer ameliorates listeriosis by accelerating infiltration of Gr‐1+ cells into the liver , 2010, European journal of immunology.

[9]  W. Born,et al.  Analysis of γδ T Cell Functions in the Mouse , 2010, The Journal of Immunology.

[10]  M. Ajuebor,et al.  Toll-like receptor 3 ligand dampens liver inflammation by stimulating Valpha 14 invariant natural killer T cells to negatively regulate gammadeltaT cells. , 2010, The American journal of pathology.

[11]  K. Mills,et al.  Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. , 2009, Immunity.

[12]  M. Veldhoen,et al.  Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. , 2009, Immunity.

[13]  A. Hayday.  Gammadelta T cells and the lymphoid stress-surveillance response. , 2009, Immunity.

[14]  A. Hayday,et al.  CD27 is a thymic determinant of the balance between interferon-γ- and interleukin 17–producing γδ T cell subsets , 2009, Nature Immunology.

[15]  C. Paget,et al.  NKT cell immune responses to viral infection , 2009, Expert opinion on therapeutic targets.

[16]  S. Way,et al.  Interleukin‐17 in host defence against bacterial, mycobacterial and fungal pathogens , 2009, Immunology.

[17]  Lan Wu,et al.  Natural killer T cells and autoimmune disease. , 2009, Current molecular medicine.

[18]  Fang Zhou,et al.  Molecular Mechanisms of IFN-γ to Up-Regulate MHC Class I Antigen Processing and Presentation , 2009, International reviews of immunology.

[19]  V. Cerundolo,et al.  Harnessing invariant NKT cells in vaccination strategies , 2009, Nature Reviews Immunology.

[20]  S. Nakae,et al.  The roles of IL‐17A in inflammatory immune responses and host defense against pathogens , 2008, Immunological reviews.

[21]  H. Kaplan,et al.  Mouse γδ T cells are capable of expressing MHC class II molecules, and of functioning as antigen-presenting cells , 2008, Journal of Neuroimmunology.

[22]  R. Steinman,et al.  Innate Vα14+ natural killer T cells mature dendritic cells, leading to strong adaptive immunity , 2007, Immunological reviews.

[23]  Anneliese O. Speak,et al.  Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. , 2007, Immunity.

[24]  M. Kronenberg,et al.  The unique role of natural killer T cells in the response to microorganisms , 2007, Nature Reviews Microbiology.

[25]  Albert Bendelac,et al.  The biology of NKT cells. , 2007, Annual review of immunology.

[26]  R. Rappuoli,et al.  Invariant NKT cells sustain specific B cell responses and memory , 2007, Proceedings of the National Academy of Sciences.

[27]  E. Gelfand,et al.  Airway hyperresponsiveness through synergy of gammadelta} T cells and NKT cells. , 2007, Journal of immunology.

[28]  S. Nutt,et al.  Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer , 2005, The Journal of experimental medicine.

[29]  L. Kaer,et al.  Innate Immunity: NKT Cells in the Spotlight , 2005, Current Biology.

[30]  B. Moser,et al.  Professional antigen-presentation function by human gammadelta T Cells. , 2005, Science.

[31]  M. Kronenberg,et al.  Going both ways: immune regulation via CD1d-dependent NKT cells. , 2004, The Journal of clinical investigation.

[32]  Yeonseok Chung,et al.  NKT cell ligand α‐galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation , 2004, European journal of immunology.

[33]  R. Steinman,et al.  The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation , 2004, The Journal of experimental medicine.

[34]  M. Brenner,et al.  Mechanisms of Vδ1 γδ T Cell Activation by Microbial Components1 , 2004, The Journal of Immunology.

[35]  M. Caligiuri,et al.  NK cell and DC interactions. , 2004, Trends in immunology.

[36]  A. Harris,et al.  NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells 1 , 2003, The Journal of Immunology.

[37]  R. Steinman,et al.  Activation of Natural Killer T Cells by -Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein , 2003 .

[38]  J. Reimann,et al.  NKT Cells Provide Help for Dendritic Cell-Dependent Priming of MHC Class I-Restricted CD8+ T Cells In Vivo 1 , 2003, The Journal of Immunology.

[39]  E. Nieuwenhuis.  CD1d-dependent, macrophage-mediated clearance of Pseudomonas aeruginosa from lung ☆ , 2002 .

[40]  D. Pellicci,et al.  Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. , 2002, Blood.

[41]  Y. Iwakura,et al.  Critical contribution of IFN‐γ and NK cells, but not perforin‐mediated cytotoxicity, to anti‐metastatic effect of α‐galactosylceramide , 2001 .

[42]  M. Smyth,et al.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[43]  M. Smyth,et al.  The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent1 , 2000, The Journal of Immunology.

[44]  J. Renauld,et al.  Cytokine Production and Killer Activity of NK/T-NK Cells Derived with IL-2, IL-15, or the Combination of IL-12 and IL-181 , 2000, The Journal of Immunology.

[45]  L. Kaer,et al.  The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. , 2000, International immunology.

[46]  L. Kaer,et al.  Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. , 2000, International immunology.

[47]  Y. Koezuka,et al.  Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. , 1999, Journal of immunology.

[48]  L. Kaer,et al.  Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. , 1999, Journal of immunology.

[49]  A. Ohta,et al.  The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells , 1999, The Journal of experimental medicine.

[50]  S. Akira,et al.  Defective NK cell activity and Th1 response in IL-18-deficient mice. , 1998, Immunity.

[51]  Hiroshi Sato,et al.  Requirement for Vα14 NKT Cells in IL-12-Mediated Rejection of Tumors , 1997 .

[52]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[53]  T. Natori,et al.  Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. , 1995, Journal of medicinal chemistry.

[54]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.